Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Share-based Compensation: 2011-2024

Historic Share-based Compensation for Niagen Bioscience (NAGE) over the last 12 years, with Dec 2024 value amounting to $3.7 million.

  • Niagen Bioscience's Share-based Compensation rose 138.91% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 28.67%. This contributed to the annual value of $3.7 million for FY2024, which is 23.05% down from last year.
  • As of FY2024, Niagen Bioscience's Share-based Compensation stood at $3.7 million, which was down 23.05% from $4.8 million recorded in FY2023.
  • In the past 5 years, Niagen Bioscience's Share-based Compensation registered a high of $6.9 million during FY2020, and its lowest value of $3.7 million during FY2024.
  • Moreover, its 3-year median value for Share-based Compensation was $4.8 million (2023), whereas its average is $4.7 million.
  • Data for Niagen Bioscience's Share-based Compensation shows a maximum YoY declined of 23.05% (in 2024) over the last 5 years.
  • Over the past 5 years, Niagen Bioscience's Share-based Compensation (Yearly) stood at $6.9 million in 2020, then dropped by 10.68% to $6.2 million in 2021, then dropped by 7.36% to $5.7 million in 2022, then declined by 17.22% to $4.8 million in 2023, then decreased by 23.05% to $3.7 million in 2024.